Back

The landscape of extrachromosomal circular DNA in medulloblastoma

Chapman, O. S.; Luebeck, J.; Wani, S.; Tiwari, A.; Pagadala, M.; Wang, S.; Larson, J. D.; Lange, J. T.; Wong, I. T.-L.; Dehkordi, S. R.; Chandran, S.; Adam, M.; Lin, Y.; Juarez, E.; Robinson, J. T.; Sridhar, S.; Malicki, D. M.; Coufal, N.; Levy, M.; Crawford, J. R.; Pomeroy, S. L.; Rich, J.; Scheuermann, R.; Carter, H.; Dixon, J.; Mischel, P. S.; Fraenkel, E.; Wechsler-Reya, R. J.; Bafna, V.; Mesirov, J. P.; Chavez, L.

2021-10-19 cancer biology
10.1101/2021.10.18.464907 bioRxiv
Show abstract

Extrachromosomal circular DNA (ecDNA) is an important driver of aggressive tumor growth, promoting high oncogene copy number, intratumoral heterogeneity, accelerated evolution of drug resistance, enhancer rewiring, and poor outcome. ecDNA has been reported in medulloblastoma (MB), the most common malignant pediatric brain tumor, but the ecDNA landscape and its association with specific MB subgroups, its impact on enhancer rewiring, and its potential clinical implications, are not known. We assembled a retrospective cohort of 468 MB patient samples with available whole genome sequencing (WGS) data covering the four major MB subgroups WNT, SHH, Group 3 and Group 4. Using computational methods for the detection and reconstruction of ecDNA1, we find ecDNA in 82 patients (18%) and observe that ecDNA+ MB patients are more than twice as likely to relapse and three times as likely to die of disease. In addition, we find that individual medulloblastoma tumors often harbor multiple ecDNAs, each containing different amplified oncogenes along with co-amplified non-coding regulatory enhancers. ecDNA was substantially more prevalent among 31 analyzed patient-derived xenograft (PDX) models and cell lines than in our patient cohort. By mapping the accessible chromatin and 3D conformation landscapes of MB tumors that harbor ecDNA, we observe frequent candidate "enhancer rewiring" events that spatially link oncogenes with co-amplified enhancers. Our study reveals the frequency and diversity of ecDNA in a subset of highly aggressive tumors and suggests enhancer rewiring as a frequent oncogenic mechanism of ecDNAs in MB. Further, these results demonstrate that ecDNA is a frequent and potent driver of poor outcome in MB patients.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.